FGFR2 Amplification is an inclusion criterion in 21 clinical trials for malignant solid tumor, of which 14 are open and 7 are closed. Of the trials that contain FGFR2 Amplification and malignant solid tumor as inclusion criteria, 8 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), 6 are phase 2 (6 open), and 3 are no phase specified (3 open) [5].

FGFR2 Amplification is an inclusion criterion in 8 clinical trials for urothelial carcinoma, of which 7 are open and 1 is closed. Of the trials that contain FGFR2 Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain FGFR2 Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 6 are phase 2 (5 open) [5].

FGFR2 Amplification is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain FGFR2 Amplification and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 6 are phase 2 (5 open) [5].

FGFR2 Amplification is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR2 Amplification and breast carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (3 open) [5].

FGFR2 Amplification is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 4 are phase 2 (4 open) [5].

FGFR2 Amplification is an inclusion criterion in 6 clinical trials for gastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR2 Amplification and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [5].

FGFR2 Amplification is an inclusion criterion in 4 clinical trials for cancer, of which 1 is open and 3 are closed. Of the trials that contain FGFR2 Amplification and cancer as inclusion criteria, 4 are phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR2 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [5].

FGFR2 Amplification is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and colorectal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 Amplification is an inclusion criterion in 2 clinical trials for sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Amplification and sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and anaplastic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Amplification and glioma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Amplification and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for lymphocytic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and lymphocytic neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Amplification is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Amplification and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].